Angiopoietins as Potential Targets in Management of Retinal Disease

The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VE...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M, Russell, Matthew W, Aziz, Aamir A, Danzig, Carl J, Weng, Christina Y, Eichenbaum, David A, Singh, Rishi P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427682/
https://www.ncbi.nlm.nih.gov/pubmed/34511878
http://dx.doi.org/10.2147/OPTH.S231801
_version_ 1783750226976178176
author Khanani, Arshad M
Russell, Matthew W
Aziz, Aamir A
Danzig, Carl J
Weng, Christina Y
Eichenbaum, David A
Singh, Rishi P
author_facet Khanani, Arshad M
Russell, Matthew W
Aziz, Aamir A
Danzig, Carl J
Weng, Christina Y
Eichenbaum, David A
Singh, Rishi P
author_sort Khanani, Arshad M
collection PubMed
description The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.
format Online
Article
Text
id pubmed-8427682
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84276822021-09-10 Angiopoietins as Potential Targets in Management of Retinal Disease Khanani, Arshad M Russell, Matthew W Aziz, Aamir A Danzig, Carl J Weng, Christina Y Eichenbaum, David A Singh, Rishi P Clin Ophthalmol Review The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections. Dove 2021-09-04 /pmc/articles/PMC8427682/ /pubmed/34511878 http://dx.doi.org/10.2147/OPTH.S231801 Text en © 2021 Khanani et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Khanani, Arshad M
Russell, Matthew W
Aziz, Aamir A
Danzig, Carl J
Weng, Christina Y
Eichenbaum, David A
Singh, Rishi P
Angiopoietins as Potential Targets in Management of Retinal Disease
title Angiopoietins as Potential Targets in Management of Retinal Disease
title_full Angiopoietins as Potential Targets in Management of Retinal Disease
title_fullStr Angiopoietins as Potential Targets in Management of Retinal Disease
title_full_unstemmed Angiopoietins as Potential Targets in Management of Retinal Disease
title_short Angiopoietins as Potential Targets in Management of Retinal Disease
title_sort angiopoietins as potential targets in management of retinal disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427682/
https://www.ncbi.nlm.nih.gov/pubmed/34511878
http://dx.doi.org/10.2147/OPTH.S231801
work_keys_str_mv AT khananiarshadm angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT russellmattheww angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT azizaamira angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT danzigcarlj angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT wengchristinay angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT eichenbaumdavida angiopoietinsaspotentialtargetsinmanagementofretinaldisease
AT singhriship angiopoietinsaspotentialtargetsinmanagementofretinaldisease

Ejemplares similares